-
Is the Pharmaceutical Innovation Model Broken? And can Open Innovation Mend it?
October 6, 2013 Editor 0
This IM Channel One Ask the Expert Q&A hosted by NineSigma shares hands-on experiences on how open Innovation can be applied to mitigate operator bias in the pharma industry. By formulating business cases that address global healthcare needs, the pharmaceutical industry can open new avenues of innovation that are built on existing solid assets, developing accessory devices and services, creating user communities (medical and/or patient) and strategies to defend against the generic erosion of revenue.
Go to SourceRelated Posts
Economic rewards of better land management: Estimated 2.3 billion tons of crops worth $1.4 trillion
SRF – a class of its own
Exit an Unprofitable Line of Business
Give Thanks, Give a Solar Powered Digital Library!
Ramesh Sawant: Story of an Entrepreneur’s Journey without the Map1
- Innovation prize set to reward African inventors
Categories: News
A Global Online Network Lets Health Professionals Share Expertise T-shirts, technology and trade: Planet Money host says experimentation, not theory, key to cutting poverty
Subscribe to our stories
Recent Posts
- Entrepreneurial Alertness, Innovation Modes, And Business Models in Small- And Medium-Sized Enterprises December 30, 2021
- The Strategic Role of Design in Driving Digital Innovation June 10, 2021
- Correction to: Hybrid mosquitoes? Evidence from rural Tanzania on how local communities conceptualize and respond to modified mosquitoes as a tool for malaria control June 10, 2021
- BRIEF FOCUS: Optimal spacing for groundnuts in smallholder farming systems June 9, 2021
- COVID-19 pandemic: impacts on the achievements of Sustainable Development Goals in Africa June 9, 2021
Categories
Archives
Popular Post-All time
- A review on biomass-based... 1k views
- Apply Now: $500,000 for Y... 798 views
- Can blockchain disrupt ge... 797 views
- Test Your Value Propositi... 749 views
- Prize-winning projects pr... 722 views